ReviewCurrent oncology (Toronto, Ont.)2014
Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management.
Review in Current oncology (Toronto, Ont.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 79 citations in OpenAlex.
- Risk Factors for Developing Venous Thromboembolism in Patients With Advanced ALK-Rearranged NSCLC.JTO clinical and research reports · 2026Article
- Echocardiographic monitoring in cancer therapy: clinical guidance for cardiologists and oncologists.Heart failure reviews · 2025Review
- Development and internal validation of a lymphoma-specific nomogram for predicting venous thromboembolism: a retrospective cohort of 790 patients.BMC cancer · 2025Article
- Cancer-Associated Venous Thromboembolic Disease: Anatomoclinical Aspects and Risk Factors.Cureus · 2025Article
- 1,8-Cineole inhibits platelet-leukocyte aggregate formation by reducing P-selectin expression.Frontiers in pharmacology · 2025Article
- Cancer-associated thromboses in non-small cell lung cancer patients withContemporary oncology (Poznan, Poland) · 2025Article
- Risk factors for pulmonary embolism in malignant tumors patients with lower limb deep vein thrombosis: a retrospective study.American journal of cancer research · 2025Article
- Article
- Mechanisms of Neutrophil Extracellular Trap Formation and Regulation in Cancers.International journal of molecular sciences · 2023Review
- Mechanism of Tumor-Platelet Communications in Cancer.Circulation research · 2023Article
- Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients-a prospective interventional study.Scientific reports · 2022Article
- Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma.Cancer medicine · 2021Observational
- Heparin beyond anti-coagulation.Current research in translational medicine · 2021Review
- Clinical presentations and outcomes in pulmonary embolism patients with cancer.Journal of thrombosis and thrombolysis · 2021Article
- Intraoperative Hypotension Increased Risk in the Oncological Patient.Anesthesiology and pain medicine · 2021Review
- Article
- Venous thromboembolism detected by FDG-PET/CT in cancer patients: a common, yet life-threatening observation.American journal of nuclear medicine and molecular imaging · 2021Article
- Risk Prediction and Treatment of LE-DVT in Patients with Chronic Radiation Intestinal Injury: A Retrospective Case-Control Study.Cancer management and research · 2021Article
- Neutrophil Extracellular Traps and Liver Disease.Seminars in liver disease · 2020Review
- Risk factors, risk assessment, and prognosis in patients with gynecological cancer and thromboembolism.The Journal of international medical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (vte) represents a major challenge in the management of patients with cancer. The malignant phenotype is associated with derangements in the coagulation cascade that can manifest as thrombosis, hemorrhage, or disseminated intravascular coagulation. The risk of vte is increased by a factor of approximately 6 in patients with cancer compared with non-cancer patients, and cancer patients account for approximately 20% of all newly diagnosed cases of vte. Postmortem studies have demonstrated rates of vte in patients with cancer to be as high as 50%. Despite that prevalence, vte prophylaxis is underused in hospitalized patients with cancer. Studies have demonstrated that hospitalized patients with cancer are less likely than their non-cancer counterparts to receive vte prophylaxis. Consensus guidelines address the aforementioned issues and emerging concepts in the area, including the use of risk-assessment models, biomarkers to identify patients at highest risk of vte, and use of anticoagulants as anticancer therapy. Despite those guidelines, a gulf exists between current recommendations and clinical practice; greater efforts are thus required to ensure effective implementation of strategies to reduce the incidence of vte in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.